accountNEW YORK - Shares of King Pharmaceuticals Inc. rose Wednesday after a Goldman Sachs analyst put the stock on a recommended list, saying King's pain drug Embeda could be approved for sale very soon. Analyst...
Join Business Exchange
to access the most
relevant content for you,
filtered by like-minded
business professionals.
Learn more
Reactions to King Pharma shares rise on Goldman recommendation
Join Business Exchange
to access the most relevant content for you, filtered by like-minded business professionals. Learn more
account